Combined Analyses of hENT1, TS, and DPD Predict Outcomes of Borderline-resectable Pancreatic Cancer
نویسندگان
چکیده
منابع مشابه
Borderline resectable pancreatic cancer.
Rigorous criteria to define "borderline resectable" pancreatic cancer are required for appropriate patient accrual into clinical trials that examine the utility of chemotherapy and/or chemoradiation that will be delivered prior to pancreatic resection for exocrine cancer. At our institution, tumor abutment of less than or equal to 180 degrees (< or = 50% of the vessel circumference) of the supe...
متن کاملNeoadjuvant Therapy for Resectable and Borderline Resectable Pancreatic Cancer
The majority of patients with localized pancreatic cancer (PC) who undergo surgery followed by adjuvant therapy will develop metastatic disease, suggesting that surgery alone is not sufficient for cure and micrometastases are present even when are not clinically detected. As such, the delivery of early systemic therapy may be a rational alternative to a surgery-first approach, in an effort to p...
متن کاملManagement of a Patient With Borderline Resectable Pancreatic Cancer
The definition and management of borderline resectability for periampullary pancreatic adenocarcinoma are evolving. In this case report, we discuss the presentation, workup, and therapeutic management of a 40-year-old man who presented with borderline resectable, periampullary pancreatic cancer and underwent a margin-negative resection following neoadjuvant chemoradiotherapy. The definition of ...
متن کاملValidation of Group B Borderline Resectable Pancreatic Cancer: Retrospective Analysis
BACKGROUND/AIMS Among borderline resectable pancreatic cancer (BRPC), group B BRPC patients have findings that are suggestive but not diagnostic of metastasis. In this study, we attempted to validate whether group B could truly be categorized as a borderline resectable group. METHODS We placed the BRPC patients into group A or group B. The survival outcomes were compared between the groups. ...
متن کاملNew developments in the management of borderline resectable pancreatic cancer.
The optimal management of borderline resectable pancreatic cancer remains unclear. Neoadjuvant chemoradiation remains the most common approach in the United States, while neoadjuvant chemotherapy alone is also widely utilized and has demonstrated efficacy but there has been no clear consensus about a regimen that would be most beneficial in this setting. We will discuss three abstracts that wer...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Anticancer Research
سال: 2017
ISSN: 0250-7005,1791-7530
DOI: 10.21873/anticanres.11587